Analyst Report: ORCL
1. EXECUTIVE SUMMARY
Oracle fell 8.76% to $119.22 on Monday 2 November 2026 after regulatory filings showed it plans to raise $20 billion through bond and share sales to fund its AI and cloud infrastructure build-out (BNN Bloomberg via headtopics). The amount matches the cap Oracle set at its investor day the previous week, so the share sale and its dilution, together with the timing, drove the reaction. After the close Oracle priced 86,206,897 shares at $116.00 (Oracle pricing release via Yahoo Finance), about 11% below the $130.67 prior close by the research assistant's calculation. The session reversed most of the 28 October investor-day rally. The stock now trades 38.27% lower year to date, close to its 52-week low of $114.08, with the next scheduled catalyst the 14 December earnings report.
2. THE CATALYST
The news broke before the open on Monday. The Reuters headline carried a 13:22 UTC timestamp (9:22 a.m. ET), and the stock opened at $125.88 against the $130.67 prior close. Oracle's filings showed a $20 billion raise split into $10 billion of common stock and $10 billion of senior notes (TheStreet, 2 November).
Oracle had told investors at its investor day that it would limit additional capital raises through fiscal 2030 to $20 billion, excluding refinancing of existing debt, with the same $10 billion equity and $10 billion gross debt split (TheStreet). The Motley Fool noted the raise fits the cap promised the week before. The financing arrived one business day after the cap was announced, and the research assistant's view is that the market treated it as a credibility test.
Pricing followed after the close: 86,206,897 shares at $116.00, plus five tranches of senior notes with coupons from 7.000% to 8.650% and maturities from 2029 to 2046 (Oracle pricing release via Yahoo Finance, 3 November).
Intraday reports of the drop varied, with the stock down about 4% premarket and about 6% in early afternoon (Reuters/headtopics; Proactive Investors). The session ended at -8.76% on volume of 58,484,300 shares, 1.87x the 50-session average.
| Session | Close | Change | Volume |
|---|---|---|---|
| 2026-10-27 | $130.53 | +3.55% | 26,026,700 |
| 2026-10-28 | $144.54 | +10.73% | 81,933,800 |
| 2026-10-29 | $139.56 | -3.45% | 39,366,900 |
| 2026-10-30 | $130.67 | -6.37% | 41,052,900 |
| 2026-11-02 | $119.22 | -8.76% | 58,484,300 |
The research brief found no sourced cause for the declines on 29 October or 30 October, so they are not attributed to anything here.
3. COMPANY PROFILE
Oracle sells software and services that build, run and support enterprise IT systems. Its cloud applications include Fusion ERP, EPM, SCM and HCM, the NetSuite suite, Oracle Health applications and Fusion Sales, Service and Marketing. It sits in the Software - Infrastructure industry within Technology. Market capitalisation is $361.42bn, with a forward P/E of 10.8, a trailing P/E of 20.5 and a dividend yield of 1.53%.
At its investor day on 28 October, Oracle set fiscal 2030 targets of revenue of $225 billion or more, a non-GAAP operating margin of 40% or higher and non-GAAP EPS of $21 or more (InvestingLive). It reaffirmed fiscal 2027 guidance (Seeking Alpha). Management said capital spending would peak this fiscal year and the next (Proactive Investors), and it expects positive free cash flow in the second half of 2028 (RTTNews) and free cash flow of $30 billion or more in fiscal 2029 (InvestingLive).
Balance-sheet figures explain the investor concern. Oracle had $125.34 billion in notes payable and other borrowings as of 31 August, against fiscal 2026 revenue of $67.36 billion (BNN Bloomberg via headtopics). One source, BigGo Finance, says it burned about $24 billion in cash in the last fiscal year. BNN Bloomberg also says investors focus on its AI spending because Oracle lacks the revenue scale of cloud rivals Microsoft and Amazon and has significant exposure to OpenAI.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The long-term targets were unchanged by the filing. The sell-off follows from the price of funding them: equity issued at $116.00 and notes carrying coupons up to 8.650%. Those coupons show what the debt market charges Oracle for its build-out. The $10 billion equity component dilutes existing holders at a price below the prior close, and the stock closed at $119.22, above the $116.00 offering price.
Comparable episode. The investor-day rally of 10.73% on 28 October was followed within four sessions by a close 17.5% below that level (the research assistant's calculation). The stock ended Monday 5.43% below its close of 26 October, the session before the rally began.
Peers. Application software peers were mixed over the same period: PLTR -3.13%, CRM -1.30%, SNPS -0.33%, ADBE +0.50%, INTU +3.23% and DDOG -8.15%. The S&P 500 fell 0.51%. Oracle's decline was far larger than the index and most peers, which points to company-specific financing as the main driver. A Stocktwits headline (headline-only, unopened) ties the broad market's decline to capex concerns. A single-source BigGo item cites Bank of America economists saying large-scale AI borrowing is one cause of rising interest rates.
Bull case. The raise fits the cap Oracle promised, so the financing plan is complete within stated limits. The equity portion is priced and the notes are sold, which removes near-term funding uncertainty. Free cash flow is targeted to turn positive in the second half of 2028 and reach $30 billion or more in fiscal 2029. At 10.8 times forward earnings the shares are priced for little of that. On the research brief's unconfirmed data, consensus targets run from $234.10 to $249.27, far above the current price, and the Mizuho target is $320 (Finbold, 14 October). No analyst rating or target change was confirmed inside the move window.
Bear case. Debt exceeds $125 billion, coupons reach 8.650% and cash burn continues for roughly two more years on the company's own timeline. Dependence on OpenAI concentrates the risk. Capital raised at $116.00 in equity sets a new reference price below where the stock traded a week earlier. The cap itself is questioned by one unconfirmed source (Analytics Insight), which says Oracle completed a $20 billion share sale between June and August 2026. That claim rests on a single source and conflicts with the framing of the cap.
5. TECHNICAL SNAPSHOT
The close of $119.22 is the lowest in the ten-session table and sits below the 50-day average of $140.90 and the 200-day average of $155.58. It is 4.5% above the 52-week low of $114.08 set on 28 July and 54.5% below the 52-week high of $262.30 from 31 October 2025. The intraday low of $118.43 on Monday was close to the close. Volume of 58,484,300 was 1.87x the 50-session average, below only the 81,933,800 recorded on 28 October. Because the latest close is the lowest in the table, no nearer support is named from the closes; the $114.08 low is the next reference below, and the $116.00 offering price lies between.
6. RISK FACTORS
- Equity supply: 86,206,897 new shares enter the market, and the stock trades against the $116.00 reference price.
- Funding costs: coupons of 7.000% to 8.650% raise interest expense on a debt load above $125 billion.
- Execution: the free cash flow targets for the second half of 2028 and fiscal 2029 depend on capital spending peaking as planned.
- Customer concentration: significant exposure to OpenAI (BNN Bloomberg).
- Sector and macro: tech-wide capex worries and the interest-rate effects of AI borrowing described by Bank of America economists (single source).
- Unexplained selling: the declines on 29 and 30 October have no confirmed cause.
Dated catalyst: next earnings on 14 December 2026, with consensus at EPS of 1.89 and revenue of $21.33bn.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks): The stock trades against the $116.00 offering price and the $114.08 52-week low. Holding above those levels would show the market absorbing the new shares. A close below $114.08 would put the stock at a new 52-week low. With no scheduled company event before December, direction depends on sector sentiment toward AI capex.
Medium term (1-3 months): The 14 December report is the main test. Results against the EPS estimate of 1.89 and revenue estimate of $21.33bn, along with any update to capex and free cash flow timing, will determine whether the investor-day credibility holds. The 50-day average at $140.90 is the level the stock would need to recover to reverse the recent trend.
Long term: The thesis is unchanged in structure. The fiscal 2030 targets and the $20 billion cap remain in place, and the financing is consistent with the cap. The case now rests on delivery of the cash flow turn in fiscal 2028 and 2029 while carrying a higher debt and share count. This is analysis only and not personal financial advice.